Literature DB >> 21779468

Duplication of Subcytoband 11E2 of Chromosome 11 Is Regularly Associated with Accelerated Tumor Development in v-abl/myc-Induced Mouse Plasmacytomas.

Francis Wiener1, Ann-Kristin Schmälter, Michael R A Mowat, Sabine Mai.   

Abstract

Chromosome 11 aberrations constitute the second most frequent chromosomal aberration in mouse plasmacytomas (PCTs) in which both the myc and abl oncogenes are constitutively expressed. In these tumors, previous G-banding studies had revealed numerical aberrations including duplication of the entire chromosome 11 or segments of telomeric bands D and E. The trisomy of chromosome 11 was always associated with accelerated pristane + v-abl/myc-induced PCT development. In the present study, PCT development was studied in a unique BALB/c congenic mouse strain, (T38HxBALB/c) F1, carrying a reciprocal translocation between chromosomes X and 11. After v-abl/myc induction, PCTs in this strain had acquired a nonrandom duplication of subcytoband 11E2. This duplication was always associated with accelerated PCT development. Corresponding synteny regions in the human and rat are changed in many tumors and involved in duplication, amplification, or translocation events. Thus, together with these synteny data, our findings strongly suggest a causal involvement of 11E2 in the acceleration of v-abl/myc-induced PCTs.

Entities:  

Keywords:  chromosome 11; mouse plasmacytoma; v-abl/myc

Year:  2010        PMID: 21779468      PMCID: PMC3092250          DOI: 10.1177/1947601910382897

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  48 in total

1.  A 6-Mb contig-based comparative gene and linkage map of the rat schwannoma tumor suppressor region at 10q32.3.

Authors:  Bernd U Koelsch; Manfred F Rajewsky; Andrea Kindler-Röhrborn
Journal:  Genomics       Date:  2005-03       Impact factor: 5.736

Review 2.  Transforming pathways activated by the v-Abl tyrosine kinase.

Authors:  Scott K Shore; Ramana V Tantravahi; E Premkumar Reddy
Journal:  Oncogene       Date:  2002-12-09       Impact factor: 9.867

3.  The induction of translocations in mouse spermatozoa. I. Kinetics of dose response with acute x-irradiation.

Authors:  A G Searle; C E Ford; E P Evans; C V Beechey; M D Burtenshaw; H M Clegg; D G Papworth
Journal:  Mutat Res       Date:  1974-02       Impact factor: 2.433

4.  The accelerating role of Abelson murine leukemia virus in murine plasmacytoma development: in vitro infection of spleen cells generates donor-type tumors after transfer to pristane-treated BALB/c mice.

Authors:  H Sugiyama; G Weber; S Silva; M Babonits; F Wiener; G Klein
Journal:  Int J Cancer       Date:  1989-08-15       Impact factor: 7.396

5.  Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.

Authors:  Maria Łastowska; Yeun-Jun Chung; Ngan Cheng Ching; Michelle Haber; Murray D Norris; Ursula R Kees; Andrew D J Pearson; Michael S Jackson
Journal:  Genes Chromosomes Cancer       Date:  2004-06       Impact factor: 5.006

6.  Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis.

Authors:  Mads Thomassen; Qihua Tan; Torben A Kruse
Journal:  Breast Cancer Res Treat       Date:  2008-02-22       Impact factor: 4.872

7.  Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5 kb: sequencing does not identify the causative gene.

Authors:  Joanne E Langan; Charlotte G Cole; Elisabeth J Huckle; Shaun Byrne; Fiona E McRonald; Lynn Rowbottom; Anthony Ellis; Joan M Shaw; Irene M Leigh; David P Kelsell; Ian Dunham; John K Field; Janet M Risk
Journal:  Hum Genet       Date:  2004-03-09       Impact factor: 4.132

8.  Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas.

Authors:  E M Weissinger; H Mischak; J Goodnight; W F Davidson; J F Mushinski
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

9.  Chromosome 15 trisomy in spontaneous and carcinogen-induced murine lymphomas of B-cell origin.

Authors:  F Wiener; M Babonits; J Spira; U Bregula; G Klein; R M Merwin; R Asofsky; M Lynes; G Haughton
Journal:  Int J Cancer       Date:  1981-01-15       Impact factor: 7.396

10.  Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus.

Authors:  S Ohno; S Migita; F Wiener; M Babonits; G Klein; J F Mushinski; M Potter
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  5 in total

1.  Assessment of the clinical relevance of 17q25.3 copy number and three-dimensional telomere organization in non-small lung cancer patients.

Authors:  Patrapim Sunpaweravong; Kelsie L Thu; Wan L Lam; Sabine Mai
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-30       Impact factor: 4.553

2.  Copy number gains of chromosome 17 identified by dual in situ hybridization in non-small cell lung cancer tissue correlate with overexpression of c-Myc.

Authors:  Patrapim Sunpaweravong; Patcharaporn Thongwatchara; Rassamee Chotipanvithayakul; Surasak Sangkhathat; Paramee Thongsuksai
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

3.  Selected telomere length changes and aberrant three-dimensional nuclear telomere organization during fast-onset mouse plasmacytomas.

Authors:  Alexandra Kuzyk; Sabine Mai
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

4.  Distinct nuclear orientation patterns for mouse chromosome 11 in normal B lymphocytes.

Authors:  Ann-Kristin Schmälter; Alexandra Kuzyk; Christiaan H Righolt; Michaela Neusser; Ortrud K Steinlein; Stefan Müller; Sabine Mai
Journal:  BMC Cell Biol       Date:  2014-06-12       Impact factor: 4.241

5.  Changes in Nuclear Orientation Patterns of Chromosome 11 during Mouse Plasmacytoma Development.

Authors:  Ann-Kristin Schmälter; Christiaan H Righolt; Alexandra Kuzyk; Sabine Mai
Journal:  Transl Oncol       Date:  2015-10       Impact factor: 4.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.